Three Rivers Announces Acquisition of Rights to Amphotec/Amphocil
Three Rivers Pharmaceuticals, LLC announced that it has completed the acquisition of worldwide ownership of Amphotec/Amphocil (amphotericin B cholesteryl sulfate complex for injection) from InterMune. Amphotec is indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immunocompromised patients. Financial terms of the agreement, which was signed and executed on May 20, 2005, were not disclosed.
()a href="http://www.newswire.ca/en/releases/archive/May2005/24/c2873.html" target="_blank">Canada NewsWire Group